Study Confirms the Ability of Castle Biosciences' Decisiondx®-Scc Test to Predict Likelihood of Benefit From Adjuvant Radiation Therapy in Patients With High-Risk Cutaneous Squamous Cell Carcinoma
研究證實了Castle Biosciences的Decisiondx®-Scc測試能夠預測高風險皮膚鱗狀細胞癌患者對輔助放療的益處可能性。
